Samuel Klein on GLP-1 Revolution, Metabolism, and the Future of Obesity Medicine
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →About this video
Creator description · original textText language: English
Dr. Samuel Klein, Division Chief and William H. Danforth Professor of Medicine and Nutritional Science at Washington University Medicine, joins The Future of Medicine for a conversation about obesity, metabolism, insulin resistance, and the revolution sparked by GLP-1 medications like Ozempic.
In this episode, Dr. Klein explains why obesity is far more biologically complex than many people realize — and why some individuals with obesity remain metabolically healthy while others develop diabetes, heart disease, and fatty liver disease.
The conversation explores how fat functions not only as stored energy, but also as an active endocrine organ that communicates with the rest of the body through hormones and inflammatory signaling molecules. Dr. Klein discusses visceral fat, insulin resistance, inflammation, and why procedures like liposuction do not produce the same metabolic benefits as weight loss through diet, surgery, or GLP-1 medications.
Dr. Klein also reflects on the unexpected rise of GLP-1 therapies, including how medications originally developed for diabetes transformed obesity treatment and may hold broader implications for cardiovascular disease, addiction, and other chronic conditions.
Together, Dr. Klein and Euan Ashley discuss the future of metabolic medicine, precision approaches to obesity care, and why understanding metabolism may reshape the future of healthcare itself.
Thank you for watching!
🔔 Subscribe for more conversations on groundbreaking medical science and innovation.
Links:
– Listen to the podcast: https://thefutureofmedicine.buzzsprout.com
– Subscribe to our channel: @stanforddepartmentofmedicine
Chapters
00:00 GLP-1 Therapy Impact
01:55 Obesity & Metabolism
03:43 Obesity: Not Always Bad ️
05:11 Fat Tissue Signals
07:05 Fat: Endocrine Function
09:02 Insulin Resistance
11:29 Liposuction Studies
12:58 Visceral Fat Impact
14:31 GLP-1 Medications
16:55 GLP-1 Unexpected Use
18:30 Metabolically Healthy
20:46 Inflammation Question
22:32 Precision Medicine
25:50 Multi-Organ System
27:22 Future of Medicine
Stanford Department of Medicine · 28 min · Source published: 2026-05-25
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.